NICE recommends GLP-1 receptor agonists for type 2 diabetes when metformin and other oral medications fail to achieve adequate glycaemic control, particularly with BMI 35 kg/m or weight-related comorbidities
The SSRS Opinion Panel is a nationally representative probability-based panel where panel members are recruited randomly in one of two ways: (a) Through invitations mailed to respondents randomly sampled from an Address-Based Sample (ABS) provided by Marketing Systems Groups (MSG) through the U.S
If you're taking a GLP-1 medication and the scale hasn't moved, you're not alone
GLP-1 receptor agonists stimulate insulin release from the pancreas only when blood glucose is elevated, suppress glucagon (which reduces liver glucose production), and slow gastric emptying to moderate glucose absorption after meals
The weight change at one year post-discontinuation was small, but depended heavily on the individual and may partly reflect the fact that many patients resumed or transitioned to other weight-management therapies rather than remaining untreated
"When I treat patients in the diabetes clinic, I see a huge variation in response to these GLP-1-based medications and it is difficult to predict this response clinically," says endocrinologist Mahesh Umapathysivam, from Adelaide University in Australia
